TOP TIERMARKET NEWSWIRE

News & sentiment

CITIUS ONCOLOGY INC Equity (CTOR) — News & AI sentiment

CITIUS ONCOLOGY INC Equity (CTOR) news roundup. 7 stories aggregated over the last 30 days. Average 30-day sentiment is 57/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

0

30d stories

7

avg sentiment 57/100

Insider net (90d)

$0

0 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

CTOR news in the last 24 hours, 7 days, 30 days and 90 days

How much CTOR coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	CTOR stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	0	—	no coverage
Last 30 days	7	57/100	CTOR headlines →
Last 90 days	12	52.2/100	CTOR headlines →

Latest stories on CTOR

Citius Oncology Reports LYMPHIR Quality-of-Life Study Results

TipRanks58 · neutralproduct/pr

Nov 4

CITIUS ONCOLOGY, INC. (CTOR) files 8-K

SEC 8-K50 · neutralgeneral

Nov 4

Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe

PR Newswire63 · neutralproduct/pr

Nov 4

CITIUS ONCOLOGY, INC. (CTOR) files 8-K

SEC 8-K50 · neutralgeneral

Oct 26

Citius reports 120% growth in shipments of LYMPHIR units to U.S. wholesalers

The Fly64 · neutralproduct/pr

Oct 26

Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026

StockTitan64 · neutralproduct/pr

Oct 26

CITIUS ONCOLOGY, INC. (CTOR) files 8-K

SEC 8-K50 · neutralgeneral

Oct 23

CITIUS ONCOLOGY, INC. (CTOR) files 8-K

SEC 8-K50 · neutralgeneral

Sep 29

Groundbreaking Research by CTOR Explores the Connection Between Bite, Facial Growth and Breathing

PR Newswire56 · neutralproduct/pr

Aug 17

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Yahoo Finance34 · bearishearnings

Aug 17

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

InvestorsHub34 · bearishearnings

Aug 17

Citius Oncology GAAP EPS of -$0.08 beats by $0.11, revenue of $1.5M misses by $4.27M

Seeking Alpha53 · neutralearnings

Aug 17

CITIUS ONCOLOGY, INC. (CTOR) files 8-K

SEC 8-K50 · neutralgeneral

Aug 14

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

PR Newswire56 · neutralearnings

Aug 14

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

StockTitan55 · neutralgeneral

Aug 14

Citius Oncology adds independent director to expanded board

TipRanks50 · neutralgeneral

Aug 12

CITIUS ONCOLOGY, INC. (CTOR) files 8-K

SEC 8-K50 · neutralgeneral

Aug 12

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

PR Newswire50 · neutralgeneral

Aug 12

Citius Oncology's LYMPHIR Gains Strong Institutional Traction as New Accounts Jump 78%

MarketChameleon73 · bullishproduct/pr

Aug 5

Citius Oncology’s LYMPHIR Achieves 78% Growth in Institutional Adoption and Near-Universal Payer Coverage August 5, 2026

MarketChameleon67 · bullishproduct/pr

Aug 5

Citius Oncology reports strong LYMPHIR commercial momentum

TipRanks67 · bullishproduct/pr

Aug 5

CITIUS ONCOLOGY, INC. (CTOR) files 8-K

SEC 8-K50 · neutralgeneral

Aug 5

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

PR Newswire67 · bullishproduct/pr

Aug 5

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

StockTitan63 · neutralproduct/pr

Jul 21

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

PR Newswire63 · neutralproduct/pr

Jul 21

Open CTOR in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →